

10-Year-Old Boy Died of Cardiac Arrest 7 Days After Moderna Shot, VAERS Data Show

By [Megan Redshaw](#)

Global Research, November 15, 2022

[Children's Health Defense](#) 14 November
2022

Region: [USA](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the **Translate Website** button below the author's name.

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Follow us on [Instagram](#) and [Twitter](#) and subscribe to our [Telegram Channel](#). Feel free to repost and share widely Global Research articles.

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of [1,458,322 reports of adverse events](#) following [COVID-19](#) vaccines were submitted between Dec. 14, 2020, and Nov. 4, 2022, to the Vaccine Adverse Event Reporting System (VAERS).

VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of [31,961 reports of deaths](#) and [265,274 serious injuries](#), including deaths, during the same time period.

There were a total of [7,783 reports of adverse events](#) following the new COVID-19 bivalent booster as of Nov. 4, 2022, with 45% attributed to [Moderna's booster](#) and 55% attributed to [Pfizer/BioNTech's booster](#). The data included a total of [61 deaths](#) and [434 serious injuries](#).

As of Nov. 10, [31.4 million people](#) have received the updated bivalent booster dose.


Of the 31,961 reported deaths, [20,381 cases](#) are attributed to Pfizer's COVID-19 vaccine, [8,696 cases](#) to Moderna, [2,773 cases](#) to Johnson & Johnson (J&J) and [no cases](#) yet reported for Novavax.

Excluding "[foreign reports](#)" to VAERS, [894,850 adverse events](#), including [15,096 deaths](#) and [93,362 serious injuries](#), were reported in the U.S. between Dec. 14, 2020, and Nov. 4, 2022.

[Foreign reports](#) are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product's labeling, the manufacturer is required to submit the report to VAERS.

Of the 15,096 [deaths reported](#) as of Nov. 4, 7% occurred within 24 hours of vaccination and 15% occurred within 48 hours of vaccination.

In the U.S., 640 million [COVID-19 vaccine doses](#) had been administered as of Nov. 2, including 381 million doses of Pfizer, 241 million doses of Moderna and 19 million doses of J&J.






Search Results

From the 11/4/2022 release of VAERS data:

Found 1,458,322 cases where Vaccine is COVID19 or COVID19-2

[Government Disclaimer on use of this data](#)

Table

 Age	  Count	Percent
< 6 Months	185	0.01%
6-11 Months	284	0.02%
1-2 Years	1,000	0.07%
3-5 Years	3,550	0.24%
6-17 Years	53,845	3.69%
18-29 Years	123,826	8.49%
30-39 Years	164,969	11.31%
40-49 Years	165,227	11.33%
50-59 Years	171,324	11.75%
60-64 Years	81,619	5.6%
65-79 Years	192,299	13.19%
80+ Years	57,846	3.97%
Unknown	442,348	30.33%
TOTAL	1,458,322	100%

Every Friday, [VAERS](#) publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed. Historically, VAERS has been shown to report only [1% of actual vaccine adverse events](#).

VAERS data from Dec. 14, 2020, to Nov. 4, 2022, for 6-month-olds to 5-year-olds show:

- [4,760 adverse events](#), including [196 cases rated as serious](#) and [8 reported deaths](#).
- [5 reports](#) of myocarditis and pericarditis (heart inflammation).

The CDC uses a [narrowed case definition](#) of “myocarditis,” which [excludes cases](#) of cardiac arrest, [ischemic strokes](#) and deaths due to heart problems that occur before one has the chance to go to the emergency department.

- [28 reports](#) of blood clotting disorders.
- [48 reports](#) of seizures.

VAERS data from Dec. 14, 2020, to Nov. 4, 2022, for 5- to 11-year-olds show:

- [15,492 adverse events](#), including [711 rated as serious](#) and [31 reported deaths](#).

- [48 reports](#) of myocarditis and pericarditis.
- [72 reports](#) of blood clotting disorders.
- [186 reports](#) of seizures.

The [latest death reported](#) in this age group was that of a 10-year-old boy who died suddenly six days after receiving a third dose of Moderna’s COVID-19 vaccine. According to the report, “It is unknown if an autopsy was performed.”

According to the company (Moderna) comment included in the report, “Cause of death was reported as cardiorespiratory arrest. Information regarding clinical evaluation, diagnostic tests, treatment provided, or autopsy reports has not been disclosed.”

VAERS data from Dec. 14, 2020, to Nov. 4, 2022, for 12- to 17-year-olds show:

- [40,268 adverse events](#), including [4,395 rated as serious](#) and [131 reported deaths](#).

According to the CDC, “VAERS data [available to the public](#) include only the initial report data to VAERS. Updated data which contains data from medical records and corrections reported during follow up are used by the government for analysis. However, for numerous reasons including data consistency, these amended data are not available to the public.”

- [269 reports](#) of anaphylaxis among 12- to 17-year-olds where the reaction was life-threatening, required treatment or resulted in death.
- [1,336 reports](#) of myocarditis and pericarditis with [1,167 cases](#) attributed to Pfizer’s vaccine.
- [303 reports](#) of blood clotting disorders with [279 cases](#) attributed to Pfizer.
- [27 cases](#) of postural orthostatic tachycardia syndrome (POTS) with all cases attributed to Pfizer’s vaccine.

VAERS data from Dec. 14, 2020, to Nov. 4, 2022, for all age groups combined, show:

- 16% of deaths were related to cardiac disorders.
- 53% of those who [died were male](#), 42% [were female](#) and the remaining death reports did not include the gender of the deceased.
- The [average age](#) of death was 72.
- As of Nov. 4, [8,665 pregnant women](#) reported adverse events related to COVID-19 vaccines, including [5,051 reports of miscarriage or premature birth](#).
- Of the [16,634 cases of Bell’s palsy](#) reported, 73% were attributed to Pfizer vaccinations, [22% to Moderna](#) and [5% to J&J](#).
- [3,066 reports](#) of Guillain-Barré syndrome.
- [10,127 reports](#) of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- [4,878 reports](#) of myocardial infarction.
- [43,929 reports](#) of blood-clotting disorders. Of those, [30,110 reports](#) were attributed to Pfizer, [9,915 reports](#) to Moderna and [3,836 reports](#) to J&J.

- [24,608 cases](#) of myocarditis and pericarditis with [18,514 cases](#) attributed to Pfizer, [5,485 cases](#) to Moderna and [423 cases](#) to J&J.
- [70 cases](#) of Creutzfeldt-Jakob disease with [57 cases](#) attributed to Pfizer, [12 cases](#) to Moderna and [1 case](#) to J&J.
- [571 cases](#) of POTS with [421 cases](#) attributed to Pfizer, [129 cases](#) to Moderna and [21 cases](#) to J&J.

[Children's Health Defense](#) (CHD) asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following [these three steps](#).

Pfizer, Moderna developing combined mRNA Omicron-flu vaccine

Pfizer and Moderna are developing a [combination COVID-19 and flu injection](#) utilizing mRNA coding for the BA4/BA5 Omicron subvariant and new mRNA coding for antigens contained in the influenza virus.

Because the COVID-19 component, which is under Emergency Use Authorization (EUA), has failed in animal studies and no human trials have been reported, that component should be off the table from the start, according to [Dr. Peter A. McCullough](#).

Combining the genetic code for both the [SARS-CoV-2 spike protein](#) and conserved proteins of influenza A and B would mean installation of the long-lasting genetic code for multiple foreign proteins in the human body.

Production of these proteins will induce an ongoing multi-pronged immune response that could create amplified side effects. mRNA coding for influenza would be a new biological product not under EUA and should have to go through the full five-year regulatory development cycle for genetic biologicals.

However, it looks like vaccine companies are trying the shortcut this development cycle by combining the non-emergency flu shot with the EUA COVID-19 vaccine.

Pfizer press release on new bivalent booster raises questions

On Nov. 4, [Pfizer announced](#) what some media outlets called “[good news](#)” about its COVID-19 bivalent booster, for which the FDA in August [granted EUA on the basis of testing conducted on eight mice](#).

In a press release, [Pfizer summarized the updated data](#) from its phase 2/3 clinical trial on the Pfizer-BioNTech Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine.

In simplest terms, the bivalent booster increased antibodies to the Omicron sublineages by a factor of 13.2, whereas the original booster increased them by a factor of only 2.9. The increase was seen only in people over age 55.

Although the [new booster](#) produced a more modest increase (9.5 fold) in antibodies in the younger age group (18-55), Pfizer chose not to report what the response was in the age-matched group who received the original booster.

Pfizer provided no comparative results in the 18-55 group and no clinical outcome differences in terms of COVID-19 infections — either in the Nov. 4 press release or in a [previous Pfizer press release](#) summarizing preliminary data.

At what point does an “increase in the neutralizing antibody response” confer “stronger protection?”

Neither BioNTech, who co-produced the Pfizer/BioNTech COVID-19 vaccine, nor the FDA knows — despite insisting the agency has enough grounds to cajole/compel/coerce those who acquired SARS-CoV-2 antibodies from a previous bout with COVID-19 to [get jabbed anyway](#).

Rutgers announces COVID vaccine trial with Pfizer, as CHD lawsuit against Rutgers advances

CHD on Nov. 7, filed a summary of its appeal in a [lawsuit against Rutgers University](#) over the university’s COVID-19 vaccine mandate.

The attorney representing CHD and 13 Rutgers University students in the lawsuit said the District Court of New Jersey didn’t follow the legal standard when it dismissed CHD’s case.

In an interview this week with [The Defender](#), Julio C. Gomez of Gomez LLC, lead counsel in the case, said U.S. District Judge Zahid N. Quraishi’s argument for granting the university’s motion to dismiss “failed to accept the facts as alleged in the plaintiffs’ complaint as true,” as required under the [legal standard on a motion to dismiss](#).

CHD on Oct. 19 [appealed the decision](#) and on Nov. 7 filed a [summary of its appeal](#).

Gomez also spoke with The Defender about Rutgers’ Nov. 4 announcement that it is [partnering with Pfizer](#) on a new clinical trial to evaluate the safety and efficacy of the bivalent COVID-19 vaccine in children under age 5.


The new clinical trial is the latest evidence of Rutgers’ conflicts of interest related to its [COVID-19 vaccine policies](#), Gomez said.

*

Note to readers: Please click the share buttons above. Follow us on Instagram and Twitter and subscribe to our Telegram Channel. Feel free to repost and share widely Global Research articles.

Megan Redshaw is a staff attorney for Children’s Health Defense and a reporter for The Defender.

Featured image is from CHD



The Worldwide Corona Crisis, Global Coup d'Etat Against Humanity

by Michel Chossudovsky

Michel Chossudovsky reviews in detail how this insidious project “destroys people’s lives”. He provides a comprehensive analysis of everything you need to know about the “pandemic” — from the medical dimensions to the economic and social repercussions, political underpinnings, and mental and psychological impacts.

“My objective as an author is to inform people worldwide and refute the official narrative which has been used as a justification to destabilize the economic and social fabric of entire countries, followed by the imposition of the “deadly” COVID-19 “vaccine”. This crisis affects humanity in its entirety: almost 8 billion people. We stand in solidarity with our fellow human beings and our children worldwide. Truth is a powerful instrument.”

ISBN: 978-0-9879389-3-0, **Year:** 2022, PDF Ebook, **Pages:** 164, 15 Chapters

Price: ~~\$11.50~~ **Get yours for FREE!** [Click here to download.](#)

We encourage you to support the eBook project by making a donation through Global Research’s [DonorBox “Worldwide Corona Crisis” Campaign Page.](#)

The original source of this article is [Children's Health Defense](#)
Copyright © [Megan Redshaw](#), [Children's Health Defense](#), 2022

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Megan Redshaw](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in

print or other forms including commercial internet sites, contact: publications@globalresearch.ca

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca